The future of pharma is going to involve some major culture shifts for a business that has long been focused on slow development cycles, proprietary molecules, and close-held secrets. That’s the word from representatives from Bayer, Boehringer Ingelheim, Healthware International and BTG, a group that ran the gamut from small to big pharma at yesterday’s Pharma Roundtable onsite at Health 2.0 in...
